Clinical Trials Browser

Has announcements × Brentuximab Vedotin × 90 days × Clear all

NCT03907488 2026-06-01

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Phase 3 Active not recruiting

994 enrolled 11 charts 1 FDA

Hodgkin Disease

NCT04404283 2026-04-20

ECHELON-3

Phase 3 Active not recruiting

239 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse